Viewing Study NCT03468335

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:22 PM
Ignite Modification Date: 2026-06-26 @ 4:10 AM
Study NCT ID: NCT03468335
Status: COMPLETED
Last Update Posted: 2025-04-17
First Post: 2018-01-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Sponsor: AIO-Studien-gGmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Locally Advanced Pancreatic Cancer View
None Metastatic Pancreatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Second-line therapy View
None Nal-IRI View
None failure gemcitabine/nab-paclitaxel View
None predictive role of 1st-line therapy View